

TABLE OF CONTENTS

CERTIFICATE	iii
DECLARATION BY THE CANDIDATE	v
COPYRIGHT TRANSFER CERTIFICATE	vii
ACKNOWLEDGEMENT	ix
TABLE OF CONTENTS	xiii
LIST OF FIGURES	xxiii
LIST OF TABLES	xxxiii
LIST OF ABBREVIATIONS	xxxv
PREFACE	xxxvii
Chapter 1. Introduction	1
1.1. Lung Cancer and Associated Challenges	1
1.2. Nanomedicine for Anticancer Drug Delivery	1
1.3. Drug Nanocrystals	2
1.3.1. Methods of Preparation	6
1.3.2. Nanocrystals for Intravenous Administration	6
1.3.3. Nanocrystals for Pulmonary Delivery	7
1.3.3.1. How Nanocrystals Escape Ciliary Clearance and Macrophage Uptake?	10
1.3.3.2. Drug Nanocrystals and Particle Deposition Pattern	11
1.3.3.3. Nanocrystals Fate in Lungs	12
1.3.4. Lipid Equipped Nanocrystals	13

1.3.5. Nanocrystals Market	15
Chapter 2. Literature Review	21
2.1. Literature Review on Nanocrystals of Anticancer Drugs	21
2.2. Literature Review on Nanocrystals for Intravenous Administration	22
2.3. Literature Review on Nanocrystals for Pulmonary Administration	23
2.4. Literature Review on Surface Modified Nanocrystals	25
2.5. Literature Review on Paclitaxel and Nanoformulations	26
2.6. Literature Review on Bosutinib and Nanoformulations	29
2.7. Literature Review on Fucoidan and Nanoformulations	31
2.8. Literature Review on Soluplus and Nanoformulations	32
Chapter 3. Polysaccharide Fucoidan Fabricated Bosutinib Nanocrystals for Pulmonary Drug Delivery: Solid State Characterization and In-vitro Assessment	35
3.1. Rationale	35
3.2. Objective	36
3.3. Materials	36
3.4. Methods	37
3.4.1. Preparation of Bosutinib Nanocrystals	37
3.4.2. Evaluation of Nanocrystals	37
3.4.3. Solid State Characterization	39
3.4.4. Saturation Solubility in Simulated Lung Fluid (SLF)	40

3.4.5. Water Contact Angle	40
3.4.6. In-Vitro Drug Dissolution in Simulated Lung Fluid	41
3.4.7. In-Vitro Mucus Diffusion	41
3.4.8. Powder Flow Study	42
3.4.9 In-Vitro Aerosolization Performance	42
3.5. Statistics	44
3.6. Results and Discussion	44
3.6.1. Preliminary Screening	44
3.6.2. Evaluation of Nanocrystals for Particle and Microscopic Characteristics	48
3.6.3. Solid State Characterization	50
3.6.4. Water Contact Angle	56
3.6.5. BET and Saturation Solubility	57
3.6.6. In-Vitro Drug Release in Simulated Lung Fluid	57
3.6.7. In-Vitro Mucus Diffusion	59
3.6.8. Powder Flow Property	59
3.6.9. In-Vitro Aerosolization Performance	60
3.7. Conclusion	61
Chapter 4. Lipid-Coated Nanocrystals of Paclitaxel as Dry Powder for Inhalation: Characterization, In-Vitro Performance, and Pharmacokinetic Assessment	63
4.1. Rationale	63

4.2. Objective	64
4.3. Materials	64
4.4. Methods	64
4.4.1. Preparation of Polysaccharide Fucoidan based Paclitaxel Nanocrystals	65
4.4.2. Preparation of Lipid Coated Paclitaxel Nanocrystals (Lipo-NCs)	65
4.4.3. Characterization of Nanocrystals	65
4.4.3.1. Particle Analysis: Size, Polydispersity Index (PDI), Zeta Potential, Encapsulation Efficiency and Drug Loading	66
4.4.3.2. Robustness to Dilution and Storage Stability	66
4.4.3.3. Microscopic Measurements	66
4.4.3.4. Solid State Characterization	67
4.4.3.5. Water Contact Angle	68
4.4.3.6. Saturation Solubility	68
4.4.4. In-Vitro Studies	69
4.4.4.1. In-Vitro Drug Release in Simulated Lung Fluid	69
4.4.4.2. Mucus Diffusion	69
4.4.4.3. Powder Flow	70
4.4.4.4. Aerosolization Performance	70
4.4.5. In-Vivo Study	71
4.5. Statistics	73
4.6. Results and Discussion	73

4.6.1. Characterization of Nanocrystals	73
4.6.2. In-Vitro Studies	87
4.6.3. In-Vivo Studies	93
4.7. Summary	98
4.8. Conclusion	99
Chapter 5. Lipid/Soluplus Stabilized Nanocrystals of Paclitaxel and Bosutinib for Synergistic Effect in Non-Small Cell Lung Cancer therapy	101
5.1. Rationale	101
5.2. Objective	101
5.3. Plan of Work	101
5.4. Materials	101
5.5. Methods	102
5.5.1. Preparation of Lipid/Soluplus Stabilized Nanocrystals of Paclitaxel and Bosutinib	102
5.5.2. Characterization of Nanocrystals	103
5.5.2.1. Particle Analysis: Hydrodynamic Size, Polydispersity Index (PDI), and Zeta Potential	103
5.5.2.2. Determination of drug content	105
5.5.2.3. Physical Stability	105
5.5.2.4. Microscopy	105
5.5.2.5. Spectroscopic Analysis	106

5.5.3. In Vitro Studies	107
5.5.3.1. Saturation Solubility	107
5.5.3.2. In Vitro Drug Release	107
5.5.3.3. In Vitro Mucus Diffusion	108
5.5.3.4. Powder Flow Property	108
5.5.3.5. In Vitro Aerosolization Performance	108
5.5.4. In Vitro Cell line Studies	109
5.5.4.1. Cell line Maintenance	109
5.5.4.2. Cell Viability Assay	110
5.5.4.3. Morphological Assessment through Acridine Orange/Ethidium Bromide (AO/EtBr) Dual Staining Technique	110
5.5.4.4. Mitochondrial Membrane Potential Study through JC-1 Staining	111
5.5.4.5. Intracellular ROS Generation via DCFH DA dye	111
5.5.4.6. Cellular Uptake	111
5.5.4.7. Cell Cycle Analysis	112
5.5.5. In Vivo Studies	112
5.5.5.1. Pharmacokinetic and Biodistribution	112
5.5.5.2. Histological Assessment	114
5.5.6. In-Vivo Imaging based Drug Distribution	114
5.6. Statistics	114
5.7. Results and Discussion	115

5.7.1. Characterization of Nanocrystals	115
5.7.1.1. Particle Analysis: Hydrodynamic Size, Polydispersity Index, Zeta Potential and Drug Content	115
5.7.1.2. Stability Assessment	115
5.7.1.3. Microscopy	116
5.7.1.4. Spectroscopic Analysis	117
5.7.2. In Vitro Studies	121
5.7.2.1. Saturation Solubility	121
5.7.2.2. In Vitro Drug Release	121
5.7.2.3. In Vitro Mucus Diffusion	122
5.7.2.4. Powder Flow Property and In Vitro Aerosolization	123
5.7.3. In Vitro Cell Line Studies	125
5.7.3.1. MTT Assay	125
5.7.3.2. Nuclear Morphological Assessment through AO/EtBr Dual Staining Technique	127
5.7.3.3. Mitochondrial Membrane Potential Study through JC-1 Staining	129
5.7.3.4. Intracellular ROS Generation via DCFH DA dye	130
5.7.3.5. Cellular Uptake	132
5.7.3.6. Cell Cycle Analysis	132
5.7.4. In Vivo Studies	134
5.7.4.1. Pharmacokinetic and Biodistribution	134

5.7.4.2. Histological Investigation	140
5.7.4.3. In-Vivo Imaging based Drug Distribution	141
5.8. Conclusion	142
Chapter 6. Formulation and Evaluation of Cetuximab-Functionalized Phospholipid-Modified and Soluplus Stabilized Nanocrystals of Paclitaxel for Non-Small Cell Lung Cancer Therapy	143
6.1. Rationale	143
6.2. Objective	143
6.3. Materials	144
6.4. Methods	145
6.4.1. Preparation of Lipid-Nanocrystals of Paclitaxel	145
6.4.2. Characterization of Nanocrystals	146
6.4.2.1. Particle Size, Polydispersity Index (PDI), Zeta-Potential, and Drug Payload	147
6.4.2.2. Physical Stability	147
6.4.2.3. Microscopic Measurements	147
6.4.2.4. Solid State Characterization	148
6.4.2.5. Surface Chemistry and Degree of Conjugation	149
6.4.2.6. In Vitro Drug Release	149
6.4.3. In Vitro Cell Lines Studies	149
6.4.3.1. Cell Line Maintenance	149
6.4.3.2. In Vitro Cytotoxicity Assay	150

6.4.3.3. Nuclear Morphological Assessment through Hoechst33342 /PI Dual Staining	150
6.4.3.4. Mitochondrial Membrane Potential Study through JC-1 Staining	151
6.4.4. Cellular Uptake	151
6.4.4.1. Cell Cycle Analysis	152
6.4.5. In Vivo Studies	152
6.4.5.1. Animals	153
6.4.5.2. Lung Cancer Model Development	153
6.4.5.3. Formulation	153
6.4.5.4. Tumor Regression, Histological Assessment and Survival Analysis	153
6.4.5.5. Pharmacokinetics and Biodistribution	154
6.5. Statistics	154
6.6. Results and Discussions	155
6.6.1. Preliminary Optimization	155
6.6.2. Characterization	160
6.6.2.1. Physicochemical and Microscopic Characterization	160
6.6.2.2. Solid State Characterization	163
6.6.2.3. Degree of Conjugation of Cetuximab and Surface Chemistry	164
6.6.2.4. In Vitro Drug Release	166
6.6.3. In Vitro Cell Line Studies	168
6.6.3.1. Cell-Cytotoxicity Assay	168
6.6.3.2. Mitochondrial Membrane Potential Study through JC-1 Staining	169

6.6.3.3. Nuclear Morphological Assessment through Hoechst33342 /PI Dual Staining	171
6.6.3.4. Cellular Uptake	173
6.6.3.5. Cell Cycle Analysis	174
6.6.4. In Vivo Studies	175
6.6.4.1. Tumor Regression, Histological Assessment and Survival Analysis	175
6.6.4.2. Pharmacokinetics and Biodistribution	178
6.7. Conclusion	182
Chapter 7. Summary & Conclusions	183
7.1. Summary	183
7.2. Conclusions	193
7.3. Future Perspective	193
Chapter 8. References	195

LIST OF FIGURES

Figure 2.1 Chemical Structure of Paclitaxel	26
Figure 2.2 Chemical Structure of Bosutinib.	29
Figure 2.3 Chemical Structure of Fucoidan.	31
Figure 2.4 Chemical Structure of Soluplus.	32
Figure 3.1 Storage stability Graphs for particle size (A), PDI (B), zeta potential (C) and drug content (D). Data were presented as mean \pm standard deviation (n=3). The statistical analysis was done by One-Way ANOVA at significance of $p < 0.05$. The “ns” denoted non-significant difference.	49
Figure 3.2 Microscopic Investigation of nanocrystals; A) SEM image; B) AFM image, and C) TEM image with Electron Diffraction (SED) Pattern.	50
Figure 3.3 Solid-state characterization of coarse drug (BTB), fucoidan (FP), physical mixture of BTB:FP (FBPM), and nanocrystals (FBNC); A) Infrared spectrum, B) XRD diffractogram, C) DSC thermograms, and D) XPS spectrum.	53
Figure 3.4 The ^{13}C CPTOSS solid-state NMR spectrum of A) coarse drug (BTB), B) fucoidan (FP) and C) nanocrystals (FBNC).	55
Figure 3.5 The water contact angle of A) Coarse drug (BTB) and B) hydrophilic fucoidan-stabilized nanocrystals (FBNC).	56
Figure 3.6 A-D) BET Isotherms for surface area analysis of nanocrystals (FBNC) compared to coarse drug (BTB); E) Saturation solubility; F) In-vitro drug release profile in SLF, and G) In-vitro diffusion study across simulated mucus of coarse drug (BTB) and its nanocrystals (FBNC). Data were presented as mean \pm standard	

deviation (n=3) and statistical significance was denoted as “****” for $p < 0.0001$, and “****” for $0.001 < p > 0.0001$. 58

Figure 3.7 Investigation of aerodynamic performance of BTB and FBNCs powder using Eight-stage Anderson cascade impactor (ACI, Westech Instruments, UK); Bar diagram showing percentage particle distribution at each stage for FBNCs as compared to BTB. Bar diagram was shown as mean \pm standard deviation (n=3). 61

Figure 4.1 A & D) SEM images; B & E) AFM images and C & F) TEM images of FPNC and Lipo-NCs, respectively. 74

Figure 4.2 Robustness of prepared nanocrystals (FPNC and Lipo-NCs) to dilutions at different folds. The data were presented as mean \pm standard deviation (n=3). One-way ANOVA was used for comparing groups using Turkey’s multiple comparison test at significance of $p < 0.05$; “ns” denoted non-significant difference. 75

Figure 4.3 Storage stability study of FPNC and Lipo-NCs for changes in particle size, PDI and zeta potential. The data were presented as mean \pm standard deviation (n=3). One-way ANOVA was used for comparison between groups using Turkey’s multiple comparison test at $p < 0.05$; “ns” denoted non-significant difference. 76

Figure 4.4 FTIR Spectrum of pure PTX, fucoidan (FP), physical mixture of drug and polymer in 1:1 (FPPM), FPNC, Soy-lecithin (SLec), cholesterol (Chol), TPGS, stearylamine, and Lipo-NCs. 77

Figure 4.5 XRD Diffraction pattern of pure PTX, fucoidan (FP), physical mixture of drug and polymer in 1:1 (FPPM), FPNC, Soy-lecithin (SLec), cholesterol (Chol), TPGS, stearylamine, and Lipo-NCs. 79

Figure 4.6 DSC thermogram of pure PTX, fucoidan (FP), physical mixture of drug and polymer in 1:1 (FPPM), FPNC, Soy-lecithin (SLec), cholesterol (Chol), TPGS, stearylamine, and Lipo-NCs.	80
Figure 4.7 A) XPS and B) CD spectrum of pure PTX, FPNC and Lipo-NCs.	81
Figure 4.8 ¹³ C solid-state NMR spectrum of FP, pure PTX and FPNC.	85
Figure 4.9 BET analysis of pure PTX and FPNC; A & B) effective surface area of PTX and FPNC, respectively; C & D) nitrogen adsorption potential of PTX and FPNC based on their effective surface area.	86
Figure 4.10 Water contact angle of pure PTX (A) FPNC (B) and Lipo-NCs (C).	87
Figure 4.11 A) Saturation solubility study in simulated lung fluid; B) In-vitro drug release profile; C) Histogram for drug diffusion across simulated mucus; and D) Angle of repose of PTX, FPNC and Lipo-NCs. Data were shown as mean ± standard deviation (n = 3) and Two-way ANOVA was used for comparison of groups using Turkey's multiple comparisons test at p < 0.0001 (****), p < 0.001 (***), p < 0.01 (**), and non-significant (ns).	91
Figure 4.12 A) Particle distributed of PTX, FPNC and Lipo-NCs at each stage of ACI. B) Histogram of particle deposited and C) Percentage drug deposited to each part and all stages of Anderson cascade impactor (ACI) assembly. Bar diagrams were shown as mean ± standard deviation (n=3).	92
Figure 4.13 A) Plasma-PTX concentration time profile, and B) Histogram for drug distribution in lung by PTX (<i>i.v.</i>), PTX (Inh.), FPNC (Inh.) and Lipo-NCs (Inh.). C-F) Histogram for drug distribution in other major organs at different time points by PTX (<i>i.v.</i>), FPNC (Inh.) and Lipo-NCs (Inh.). All data were shown as mean ± standard deviation (n = 3) and Two-way ANOVA was used for comparison of groups	

using Turkey's multiple comparisons test at $p < 0.0001$ (****), $p < 0.001$ (***), $p < 0.01$ (**), $p < 0.05$ (*), and non-significant (ns). 95

Figure 5.1 Schematic representation of preparation of soluplus stabilized and lipid coated nanocrystals of paclitaxel and bosutinib. 104

Figure 5.2 Microscopic investigation of PTX-NCs, Lipo/PTX-NCs, BTB-NCs and Lipo-BTB-NCs using SEM, AFM, and TEM. 117

Figure 5.3 Spectroscopic analysis of PTX, PTX-NCs, Lipo/PTX-NCs, BTB, BTB-NCs and Lipo/BTB-NCs; A) FTIR, B) XRD and C) DSC. 120

Figure 5.4 A) Saturation solubility study; B) In vitro drug release profile of PTX+BTB, PTX-NCs+BTB-NCs and Lipo/BTB-NCs+Lipo/PTX-NCs in simulated lung fluid. The data were presented as mean \pm standard deviation (n=3), and statistical analysis was done by two-way ANOVA using Turkey's multiple comparison test at significance of $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***), and $p < 0.0001$ (****) were considered significant, while $p > 0.05$ (ns) considered non-significant. 122

Figure 5.5 In vitro drug diffusion across simulated mucus. The data were presented as mean \pm standard deviation (n=3), and statistical analysis was done by two-way ANOVA using Turkey's multiple comparison test at significance of $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***), and $p < 0.0001$ (****) were considered significantly different, while $p > 0.05$ (ns) considered non-significant. 123

Figure 5.6 In vitro aerosolization performance of mixture of Lipo/PTX-NCs and Lipo/BTB-NCs. Bar diagrams were shown as mean \pm standard deviation (n=3). 124

Figure 5.7 Cell viability assay of PTX, BTB and their combination on A549 cancer cells. Bar diagrams were shown as mean \pm standard deviation (n=3). 126

Figure 5.8 Cell viability assay of PTX-NCs, BTB-NCs, Lipo/PTX-NCs, and Lipo/BTB-NCs on A549 cancer cells. Bar diagrams were shown as mean \pm standard deviation (n=3). 126

Figure 5.9 Cell viability assay of nanocrystals combination; PTX-NCs: BTB-NCs and Lipo/PTX-NCs: Lipo/BTB-NCs on A549 cancer cells. Bar diagrams were shown as mean \pm standard deviation (n=3). 127

Figure 5.10 Morphological changes determined by Acridine orange/ethidium bromide (AO/EtBr) dual staining technique in A549 cancer cells on treatment with pure PTX, pure BTB, pure (PTX + BTB), PTX-NCs, BTB-NCs, PTX-NCs+BTB-NCs, Lipo/PTX-NCs+Lipo/BTB-NCs. 128

Figure 5.11 Detection of mitochondrial membrane potential through JC-1 staining, green fluorescence was due to mitochondrial depolarization on treatment with pure PTX, pure BTB, pure (PTX + BTB), PTX-NCs, BTB-NCs, PTX-NCs+BTB-NCs, Lipo/PTX-NCs+Lipo/BTB-NCs due to formation of j-monomers as a result of JC-1 dye binding with damaged mitochondria. Scale bar = 100 μ m. 129

Figure 5.12 Detection of intracellular ROS using DCFH-DA (2',7'-dichlorodihydrofluorescein diacetate) dye when treated with pure PTX, pure BTB, pure (PTX + BTB), PTX-NCs, BTB-NCs, PTX-NCs+BTB-NCs, Lipo/PTX-NCs+Lipo/BTB-NCs. 131

Figure 5.13 Fluorescence microscopic images of A549 cells showing cytoplasmic uptake of Free C6, PTX-NCs, BTB-NCs PTX-NCs+BTB-NCs, Lipo/PTX-NCs+Lipo/BTB-NCs post 12 h of incubation. Cytoplasmic uptake showed green fluorescence and nuclear morphology was seen in blue fluorescence. Each scale bar represents 100 μ m. 133

Figure 5.14 Quantitative cell cycle analysis showing different cell cycle stages (Sub G1, G1, S, and G2/M) of Control (untreated), pure PTX, pure BTB, pure (PTX+BTB), PTX-NCs+BTB-NCs, Lipo/PTX-NCs+Lipo/BTB-NCs, through flow cytometry. 134

Figure 5.15 Pharmacokinetic and biodistribution study of intravenously administered PTX+BTB and Lipo/PTX-NCs+Lipo/BTB-NCs compared to intratracheally administered Lipo/PTX-NCs+Lipo/BTB-NCs; A) Plasma concentration time profile; B) lung tissue concentration time profile. The data were presented as mean \pm standard deviation (n=3). 135

Figure 5.16 Biodistribution of drug in all other major organs including Liver, Kidney, Spleen and Heart. The data were presented as mean \pm standard deviation (n=3), and statistical analysis was done by two-way ANOVA using Turkey's multiple comparison test at value of $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***), and $p < 0.0001$ (****) as significant, while $p > 0.05$ (ns) considered non-significant. 137

Figure 5.17 Histological investigation of all major organs including liver, lungs, kidney, spleen and heart, post treatment with target drugs and formulations; Group 1 (G1: PTX+BTB via intravenous administration), Group 2 (G2: Lipo/PTX-NCs + Lipo/BTB-NCs via intravenous administration) and Group 3 (G3: Lipo/PTX-NCs + Lipo/BTB-NCs via intratracheal administration); Yellow colored arrow showing signs of organ toxicity. 140

Figure 5.18 In-vivo imaging for tracking the biodistribution of combination of lipid nanocrystals of paclitaxel and bosutinib, intratracheally administered. A) images of organs collected at various time points post intratracheal administration of lipid nanocrystals (Lipo/DiD-PTX-NCs + Lipo/DiD-BTB-NCs). B) Histogram of time vs

fluorescence intensity for quantitative estimation of nanocrystals distribution in each organ on pulmonary administration as dry powder for inhalation. 141

Figure 6.1 Investigation of storage stability of prepared nanocrystals for hydrodynamic particle size, polydispersity index (PDI) and zeta potential. Data were presented as mean \pm standard deviation (n=3). One-way ANOVA was applied for comparison using Turkey's comparison test. Values with $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***), and $p < 0.0001$ (****) were considered significant, while $p > 0.05$ (ns) considered non-significant. 161

Figure 6.2 Microscopic investigation of nanocrystals; SEM, AFM, and TEM images of PTX-NCs (A-C), Lipid/PTX-NCs (D-F), and Cmab/Lipid/PTX-NCs (G-I). 163

Figure 6.3 Spectroscopic analysis including FTIR (A), XRD (B), and DSC (C) of PTX, Soluplus®, PTX-NCs, HSPC, Chol, TPGS, Lipid/PTX-NCs, and Cmab/Lipid/PTX-NCs. 165

Figure 6.4 XPS spectrum of PTX, Lipid/PTX-NCs and Cmab/Lipid/PTX-NCs for investigating lipid and Cmab conjugation on nanocrystals surface. 166

Figure 6.5 In vitro drug release profile of PTX, PTX-NCs, Lipid/PTX-NCs and Cmab/Lipid/PTX-NCs, at pH.7.4. Data were presented as mean \pm standard deviation (n=3). One-way ANOVA was applied for comparison using Turkey's comparison test at $p < 0.0001$ (****) as significant, while $p > 0.05$ (ns) considered non-significant. 167

Figure 6.6 Cell viability assay of drug and nanocrystals in A549 cancer cells. Bars were shown as mean \pm standard deviation (n=3). 169

Figure 6.7 Detection of mitochondrial membrane potential through JC-1 staining, green fluorescence was due to mitochondrial depolarization on treatment with PTX,

PTX-NCs, Lipid/PTX-NCs, and C-mab/Lipid/PTX-NCs due to formation of j-monomers as a result of JC-1 dye 170

Figure 6.8 Nuclear morphological changes during apoptosis post-treatment to PTX, PTX-NCs, Lipid/PTX-NCs, and C-mab/Lipid/PTX-NCs, assessed through the Hoechst33342/PI dual staining method. Yellow, white, and red arrows indicated live, early apoptotic, and late apoptosis. 172

Figure 6.9 Fluorescence microscopic images of A549 cells showing cytoplasmic uptake of Free C6, pure PTX, PTX-NCs, Lipid/PTX-NCs, and C-mab/Lipid/PTX-NCs post 12 h of incubation. Cytoplasmic uptake showed green fluorescence and nuclear morphology was seen in blue fluorescence. Each scale bar represents 100 μm . 173

Figure 6.10 Quantitative cell cycle analysis showing different cell cycle stages (Sub G1, G1, S, and G2/M) of Control (untreated), Placebo formulation, pure PTX, PTX-NCs, Lipid/PTX-NCs, and C-mab/Lipid/PTX-NCs, through flow cytometry. 175

Figure 6.11 A) Change in body weight as a response to intravenous administration of pure PTX, PTX-NCs, Lipid/PTX-NCs, and C-mab/Lipid/PTX-NCs in mice with Benzo[a] pyrene-induced lung cancer; B) The histological assessment of lungs of pure PTX, PTX-NCs, Lipid/PTX-NC; C) Kaplan-Mier survival plot. 177

Figure 6.12 Plasma concentration and lung tissue concentration time profile of PTX and nanocrystals (PTX-NCs, Lipid/PTX-NCs and C-mab/Lipid/PTX-NCs). Data were presented as mean \pm standard deviation (n=3). 178

Figure 6.13 Drug distribution in major organs other than lungs including brain, heart, kidney, liver, and spleen on intravenous administration of PTX, PTX-NCs, Lipid/PTX-NCs, and C-mab/Lipid/PTX-NCs. Data were presented as mean \pm

standard deviation (n=3). One-way ANOVA was applied for comparison using Turkey's multiple comparison test at $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***), and $p < 0.0001$ (****) as significant, while $p > 0.05$ (ns) considered non-significant. 181

LIST OF TABLES

Table 1.1 Technology Used for Nanocrystals Formulation	4
Table 1.2 Nanocrystals in Market	17
Table 2.1 Physicochemical Properties of Paclitaxel.	28
Table 2.2 Physicochemical Properties of Bosutinib	30
Table 2.3 Physicochemical Properties of Fucoidan	32
Table 2.4 Physicochemical Properties of Soluplus	33
Table 3.1 Effective cut-off diameter of each stage of impactor.	44
Table 3.2 Formulation Optimization of Fucoidan Fabricated Nanocrystals.	46
Table 4.1 Effective cut-off diameter of each stage of impactor.	71
Table 4.2 Solution and Solid-state ¹³ C NMR chemical shifts of pure PTX and FPNC.	83
Table 4.3 Drug release fitted to various release models.	89
Table 4.4 Pharmacokinetic parameters for plasma concentration time profile of PTX administered intravenously and intratracheally to the rats.	96
Table 4.5 Pharmacokinetic parameters for lung concentration time profile of PTX administered intravenously and intratracheally administration to the rats.	97
Table 5.1 Effective cut-off diameter of each stage of impactor.	109
Table 5.2 Particle characteristics of prepared nanocrystals.	115
Table 5.3 Pharmacokinetic parameters for plasma PTX-concentration time profiles.	138
Table 5.4. Pharmacokinetic parameters for lung PTX-concentration time profiles.	139
Table 6.1 Optimization of soluplus stabilized paclitaxel nanocrystals.	157

Table 6.2 Optimization of lipid modified nanocrystals of paclitaxel.	159
Table 6.3 Pharmacokinetic parameters for plasma concentration-time profile of intravenously administered pure drug and nanocrystals.	179
Table 6.4 Pharmacokinetic parameters for Lung concentration-time profile of intravenously administered pure drug and nanocrystals.	180

LIST OF ABBREVIATIONS

ACI	: Anderson cascade impactor
BET	: Brunner-Emmett-Teller
BTB	: Bosutinib
BSA	: Bovine serum albumin
C6	: Coumarin-6
Chol	: Cholesterol
Cmab	: Cetuximab
DLS	: Dynamic light scattering
DMAP	: N, 4-Dimethylaminopyridine
DMEM	: Dulbecco's Modified Eagle Medium
DPIs	: Dry powder for inhalation
DSC	: Differential scanning calorimetry
ED	: Emitted dose
EDC	: 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
EPR	: Enhanced permeation and retention effect,
FBS	: Fetal Bovine Serum
FP	: Fucoidan
FPD	: Fine particle dose
FPF	: Fine particle fraction
FTIR	: Fourier Transform Infrared Spectroscopy
H-33342	: Hoechst 33342 dye
HEC	: Hydroxyethylcellulose
HR-TEM	: High-Resolution Transmission Electron Microscope

HSPC	: Hydrogenated Soyphosphatidylcholine
<i>i.v.</i>	: Intravenous
IC50	: Half maximal inhibitory concentration (IC50)
Inh.	: Inhalation
MPS	: Mononuclear phagocytic system
MTT	: (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide)
NCs	: Nanocrystals
NSCLC	: Non-small cell lung cancer
PBS	: Phosphate Buffer Saline
PI	: Propidium iodide
PDI	: Polydispersity index
PTX	: Paclitaxel
RES	: Reticuloendothelial system
RF	: Respirable fraction
ROS	: Reactive Oxygen Species
SEM	: Scanning electron microscope
SLF	: Simulated lung fluid
Sol	: Soluplus
SPM	: Scanning probe microscope
ss-NMR	: Solid-state NMR
TKIs	: Tyrosine kinase inhibitors
TPGS	: Tocopherol polyethylene glycol succinate
USP	: United States of Pharmacopeia
XPS	: X-ray photoelectron spectroscopy
XRD	: Powder X-ray diffraction